Cancer
CatalYm, a world leader in neutralizing GDF-15 in cancer and cachexia, presented updated long-term data from its ongoing GDFATHER-1/2a trial at the European Society of Medical Oncology (ESMO) Congress 2025. The data provide further evidence that Growth Differentiation Factor-15 (GDF-15) blockade by visugromab can reverse resistance to PD-(L)
Cancer research
Researchers have been working tirelessly to combat the rising incidence of lung cancer, a leading cause of morbidity and mortality worldwide. Among the various subtypes of lung cancer, non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases, with a significant proportion of patients still relapsing after undergoing
Cancer
Patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL) have limited treatment options, but a new combination therapy of epigenetic therapy with an anti-PD-1 antibody shows promising results. The study, published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR), suggests that the
Cancer
Researchers from the University of Texas MD Anderson Cancer Center conducted a systematic review and network meta-analysis to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy in the first-line treatment of gastric/gastroesophageal junction cancer. The study aimed to compare the outcomes of tislelizumab with other approved
Cancer
Researchers from Humanitas University in Milan, Italy have conducted a prospective observational study to evaluate the safety of romosozumab in women with cancer and osteoporosis, who are at high risk of fractures. The study involved 131 patients, with 19% having a history of cancer. The results showed that romosozumab was
Cancer
Researchers from Sun Yat-sen University Cancer Center have made a significant breakthrough in the treatment of glioblastoma, a highly aggressive form of brain cancer. By developing a novel biomimetic delivery system, the team has been able to activate glioma-associated macrophages (GAMs) to enhance the repolarization and phagocytic abilities of these
Cancer research
Researchers in Shanghai have made significant strides in cancer gene therapy by harnessing the power of natural killer (NK) cells. According to a recent study published in Critical Reviews In Oncology Hematology, genetic engineering strategies have been optimized to enhance NK cell antitumor function, offering new hope for cancer treatment.
Cancer research
Researchers from the University of Milan have made significant progress in understanding how to predict the response to immunotherapy in HER2-negative breast cancer patients. By developing an algorithmic strategy called ARIADNE, which analyzes gene expression data from bioptic samples based on epithelial-mesenchymal phenotypes, the team was able to predict the
Cancer research
Researchers at the University of Washington have made significant strides in the field of cancer gene therapy, developing a new mRNA delivery platform that outperforms existing solutions. The platform, called PFHA-PEI-mRNA-HP, utilizes a combination of fluorination and heparinization of low molecular weight polyethylenimine (PEI)-based mRNA complexes to enhance performance.
Immunotherapy
Sindh Chief Minister (CM) Syed Murad Ali Shah launched a province-wide anti-polio campaign by administering drops to two newborns at KMC Gizri Maternity Home, marking the start of a week-long effort to vaccinate over 10.6 million children under five across Sindh. The campaign, which runs from October 13 to
Cancer research
A groundbreaking study published in the JAMA Oncology journal has investigated the effectiveness of immunotherapy versus best supportive care in treating patients with hepatocellular cancer and Child-Pugh class B liver dysfunction. The research, conducted by a team of researchers from Imperial College London, examined the outcomes of patients who received
Cancer
Researchers from Huazhong University of Science and Technology have made significant breakthroughs in understanding the link between metabolic dysregulation and immune regulation in endometrial cancer (EC). Their studies reveal a pivotal role of estrogen-related receptor (ERR) alpha in promoting EC progression through mitochondrial lipid metabolism and macrophage-driven immunosuppression. This research
